medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 1

<< Back Next >>

Rev Mex Urol 2020; 80 (1)

Clear cell renal cell carcinoma detection leading to von Hippel-Lindau disease diagnosis: A case report

Martínez-Valeriano DA, Vásquez-Ciriaco S, Jiménez-Rivera E, García-Manzano RA, Barker-Antonio A, Dávila-Ruiz EO, García-Espinoza JA

Language: Spanish
References: 14
Page: 1-8
PDF size: 399.97 Kb.


ABSTRACT

Background: Von Hippel-Lindau disease is caused by mutations of the VHL tumor-suppressor gene and results in the development of different neoplasias in the central nervous system, eye, and abdomen. Its incidence is low, but patients that develop clear cell renal cell carcinoma have the highest mortality rate.
Clinical case: A 45-year-old woman, with a family history of central nervous system and abdominal neoplasias, sought medical attention due to a progressively growing mass in the left flank. A kidney tumor was corroborated through an imaging study, and she underwent left radical nephrectomy. The diagnosis of clear cell renal cell carcinoma was confirmed. In the subsequent approach, she was also diagnosed with von Hippel-Lindau type I disease.
Conclusions: Von Hippel-Lindau disease presents with different neoplastic manifestations, and that of clear cell renal cell carcinoma has the highest morbidity and mortality rates. When there is a family history, its early detection is essential for improving outcome and opportunely diagnosing other neoplasias resulting from the disease.


REFERENCES

  1. v. Hippel E. Über eine sehr seltene Erkrankung der Netzhaut. Graefes Arhiv für Ophthalmologie. 1904 Aug 1;59(1):83–106. doi: 10.1007/ BF01994821

  2. Lindau A. ZUR FRAGE DER ANGIOMATOSIS RETINæ UND IHRER HIRNKOMPLIKATIONEN. Acta Ophthalmologica. 1926;4(1–2):193–226. doi: https://doi.org/10.1111/j.1755-3768.1926. tb07786.x

  3. A. Crossey P, M. Richards F, Foster K, Reen JS, Prowse A, Latlf F, et al. Identification of intragenic mutations in the Von Hippel — Lindau disease tumour suppressor gene andcorrelation with disease phenotype. Hum Mol Genet. 1994 Aug 1;3(8):1303–8. doi: https://doi. org/10.1093/hmg/3.8.1303

  4. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001 May 1;10(10):1029–38. doi: https://doi. org/10.1093/hmg/10.10.1029

  5. Neumann HPH, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. The Lancet. 1991 May 4;337(8749):1052–4. doi: https://doi. org/10.1016/0140-6736(91)91705-Y

  6. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin Jr WG. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001 May 1;10(10):1019–27. doi: https://doi. org/10.1093/hmg/10.10.1019

  7. Franke G, Bausch B, Hoffmann MM, Cybulla M, Wilhelm C, Kohlhase J, et al. Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype–phenotype correlations in VHL patients. Human Mutation. 2009;30(5):776–86. doi: https://doi. org/10.1002/humu.20948

  8. Kim E, Zschiedrich S. Renal Cell Carcinoma in von Hippel–Lindau Disease—From Tumor Genetics to Novel Therapeutic Strategies. Front Pediatr. 2018;6. [accessed 11 Feb 2020] Available from: https://www.frontiersin.org/ articles/10.3389/fped.2018.00016/full

  9. Findeis-Hosey J, McMahon K, Findeis S. Von Hippel-Lindau Disease. J Pediatr Genet. 2016 Apr 4;5(2):116–23. doi: https://doi. org/10.1055/s-0036-1579757

  10. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013 Aug;45(8):860–7. doi: https://doi. org/10.1038/ng.2699

  11. Noonan HR, Metelo AM, Kamei CN, Peterson RT, Drummond IA, Iliopoulos O. Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma. Disease Models & Mechanisms. 2016 Aug 1;9(8):873–84. doi: https://doi.org/10.1242/dmm.024380

  12. Duffey Branden G., Choyke Peter L., Glenn Gladys, Grubb Robert L., Venzon David, Linehan W. Marston, et al. The relationship between renal tumor size and metastases in patients with von hippel-lindau disease. Journal of Urology. 2004 Jul 1;172(1):63–5. doi: https:// doi.org/10.1097/01.ju.0000132127.79974.3f

  13. Jilg CA, Neumann HPH, Gläsker S, Schäfer O, Leiber C, Ardelt PU, et al. Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological longterm follow-up. Familial Cancer. 2012 Sep 1;11(3):387–94. doi: https://doi.org/10.1007/ s10689-012-9525-7

  14. Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: A clinical and scientific review. Eur J Hum Genet. 2011 Jun;19(6):617–23. doi: https://doi.org/10.1038/ejhg.2010.175.




2020     |     www.medigraphic.com